Delving into the Latest Updates on Shihezi University with Synapse

Overview

Tags

Infectious Diseases

Digestive System Disorders

Skin and Musculoskeletal Diseases

Fusion protein

Small molecule drug

Exosomes

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	3

Top 5 Drug Type	Count

Small molecule drug	1
mRNA	1
Exosomes	1
Fusion protein	1

Top 5 Target	Count

Mycobacterium tuberculosis antigen	1
UPF3B(UPF3B regulator of nonsense mediated mRNA decay)	1
PTPN3(protein tyrosine phosphatase non-receptor type 3)	1

This is a retrospective, multicenter, observational study aimed at assessing stent apposition for coronary stent implantation by an optical coherence tomography system constructed by deep learning algorithms and evaluating the prognosis of patients after stent implantation in conjunction with multimodal diagnostic and therapeutic information.

Start Date20 Aug 2024

Sponsor / Collaborator

First Affiliated Hospital of Xinjiang Medical University

[+1]

NCT05291325

/ CompletedNot ApplicableIIT

Application of Linaclotide Capsule in Bowel Preparation for Colonoscopy: a Multicenter, Randomized, Controlled Clinical Study

The clinical purpose of this study was to investigate whether the adjuvant application of linaclotide in bowel preparation for colonoscopy could improve the quality of bowel preparation or reduce the dosage of laxatives.

Start Date25 May 2022

Sponsor / Collaborator

Changhai Hospital of Shanghai

[+17]

100 Clinical Results associated with Shihezi University

Login to view more data

0 Patents (Medical) associated with Shihezi University

Login to view more data

21,384

Literatures (Medical) associated with Shihezi University

31 Dec 2025·Energy Sources, Part A: Recovery, Utilization, and Environmental Effects

Optimization of semi-continuous cultivation conditions for the improvement of lipid productivity from thermo-tolerant Chlorella vulgaris XJW

Author: Dai, Bin ; Xu, Xiaolin ; Bai, Lanli

Chlorella vulgaris XJW (C. vulgaris XJW), one temperature tolerable microalgae with biodiesel production potential, was selected from Ulungur Lake in Xinjiang.In this research, optimal semi-continuous cultivation conditions were obtained by employing uniform design method.The total biomass and lipid productivity of C. vulgaris XJW cultured with semi-continuous mode in Column photobioreactor were affected by renewal rate, renewal period, nitrogen concentration and phosphorus concentrationAccording to the regression equation, the optimal semi-continuous cultivation conditions for the total biomass of C. vulgaris XJW was renewal rate of 33%, renewal period of 4 days, NaNO₃ concentration of 0.69 g·L^-1 and K₂HPO₄ concentration of 0.02 g·L^-1.In the optimal conditions, the maximum total biomass of C. vulgaris XJW was 3.682 g·L^-1, which was 20.1% higher than the highest value in unoptimized semi-continuous cultivation conditions, and 2.6 times higher than that in batch cultivation.Meanwhile, the optimal semi-continuous cultivation conditions for lipid productivity of C. vulgaris XJW was renewal rate of 27%, renewal period of 3 days, NaNO₃ concentration of 1.03 g·L^-1 and K₂HPO₄ concentration of 0.02 g·L^-1.In the optimal conditions, the maximum lipid productivity of C. vulgaris XJW was 110.43 mg·L^-1d^-1, which was 16.8% higher than the highest value in unoptimized semi-continuous cultivation conditions, and 2.7 times higher than that in batch cultivation.Results were consistent with the predicted values obtained by model equations, which confirmed the reliability of model equations.The models achieved in this work could accurately predict the semi-continuous cultivation conditions of C. vulgaris XJW with total biomass and lipid productivity as indicators.Good cultivation model would make the large-scale cultivation of this kind of microalgae possible, providing enough materials for the biodiesel production

01 Dec 2025·Molecular Biology Reports

Rapid detection assays for Bacillus anthracis, Yersinia pestis, and Brucella spp. via triplex-recombinase polymerase amplification

Article

Author: Wang, Yuanzhi ; Wang, Hengliang ; Feng, Meijie ; Wang, Dongshu ; Liu, Xiankai ; Zhang, Yan ; Lyu, Yufei ; Meng, Ying ; Zhu, Li ; Pan, Chao ; Ma, Jinping

BACKGROUNDBacillus anthracis (B. anthracis), Yersinia pestis (Y. pestis), and Brucella spp. are zoonotic bacteria that cause anthrax, plague, and brucellosis, respectively. Outbreaks typically occur in remote regions with poor transportation and limited laboratory testing. Therefore, a simple, sensitive, multiplex nucleic acid detection method is essential for effective disease management and control.METHODSPrimers and probes for the three pathogens were designed to reduce interference from related strains. Three recombinase polymerase amplification (RPA) reactions were conducted at 39 °C for 10 min to produce species-specific fluorescence signals for the three pathogens. These were integrated, and conditions were optimized for rapid, sensitive triplex-RPA assays without cross-reactivity. A triplex-RPA reaction with lateral flow dipsticks (LFDs) was developed and applied to blood samples, newly isolated strains, and simulated samples.RESULTSHighly sensitive and specific primers and probes were developed, achieving a maximum sensitivity of 1 copy/µL in single-reaction RPA. The optimized triplex RPA detection technique, combined with fluorescence, effectively identified B. anthracis, Y. pestis, and Brucella spp. within 20 min, whereas LFDs achieved detection in 10 min. The assay also performed comparably to conventional polymerase chain reaction techniques when tested on blood samples, newly isolated strains, and simulated samples.CONCLUSIONSThis study offers reliable methods for detecting B. anthracis, Y. pestis, and Brucella spp. in rural hospitals and public health initiatives.

01 Dec 2025·Cancer Nanotechnology

Nanocomplex hyaluronic acid/ganciclovir@ZIF-8 for ganciclovir efficient delivery and targeted anti-KSHV treatment

Author: Liu, Zhiyong ; Li, Dongmei ; Cao, Dongdong ; Liu, Chengjing ; Gu, Wenyi ; Xu, Qianhe ; Li, Fangling

Abstract: Kaposi′s sarcoma-associated herpesvirus (KSHV) infection can cause a variety of tumors and is one of the leading causes of death in acquired immune deficiency syndrome (AIDS) patients.As a small mol. antiviral drug, ganciclovir (GCV) can be used for anti-KSHV treatment.However, GCV has non-specific action and toxic side effects in vivo, and how to make it safer and more effective against KSHV is still a great challenge.By encapsulating GCV into metal-organic skeleton material zeolitic imidazolate framework-8 (ZIF-8) and further modification of hyaluronic acid (HA), the nanomedical delivery system of GCV (HA/GCV@ZIF-8) has been developed for efficient GCV delivery and targeted anti-KSHV treatment.The modification of HA leads to the targeted binding of the nanocomplex with the overexpressed CD44 receptors in tumor cell membranes, resulting in the increased accumulation and cellular uptake of GCV.Exploiting the decomposition property of ZIF-8 under acidic conditions, the nanocomplex exhibits pH-responsive drug release in slightly acidic tumor environment.In addition, HA/GCV@ZIF-8 not only suppresses expression of KSHV pathogenic genes with less drug dose, but also inhibits the ability of cell proliferation and migration.In vivo anti-tumor results showed that HA/GCV@ZIF-8 accumulated in tumor cells and effectively inhibited tumor growth.The results open a gate for the targeted anti-KSHV treatment.Graphical Abstract:

100 Deals associated with Shihezi University

Login to view more data

100 Translational Medicine associated with Shihezi University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

1

Preclinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lupeol	Metabolic dysfunction-associated steatotic liver disease More	Preclinical
CN118121619 ( UPF3B )	Liver Diseases More	Discovery
CN116814757 ( PTPN3 )	Infectious Diseases More	Discovery
CN118652349 ( Mycobacterium tuberculosis antigen )	Infectious Diseases More	Discovery